Company News: ALL, AUXL, HUM, ACOR, ONB, PAET, HAE, JAZZ, KEG

• Allstate Corporation (NYSE:ALL) reported Q2 loss of $1.23, lower than the Zacks Consensus Estimate of $1.53 per share. Revenues for the quarter increased by 5% year-over-year to $8.08 billion, exceeding the Zacks Consensus Estimate of $6.91 billion

• Auxilium Pharmaceuticals (NASDAQ:AUXL) posted a Q2 loss of $0.11 per share, less than the analysts’ estimate for a loss of $0.19 per share. Revenues for the quarter increased 30.5% year-over-year to $65.9 million

• Humana (NYSE:HUM) reported Q2 EPS of $2.50, beating the Zacks Consensus Estimate of $2.07 per share. Revenues increased 8.1% year-over-year to $9.28 billion, lower than the Zacks Consensus Estimate of $9.32 billion

• Acorda Therapeutics (NASDAQ:ACOR) posted Q2 EPS of $0.01. Revenues for the pharma company rose 52.6% year-over-year to $65.3 million

• Share prices of Old National Bancorp. (NYSE:ONB) gained 7.25% after the bank-holding company posted second quarter earnings results that came in above expectations

• PAETEC Holding Corp (NASDAQ:PAET) agreed to be acquired by Windstream Corp for a deal valued at $891 million. Reacting to the news, shares of PAETEC increased 20.59%

• Share prices of blood-processing device maker, Haemonetics Corp. (NYSE:HAE) fell 10.90% after the company lowered its earnings forecast for the 2011 fiscal

• Analysts at Jefferies upgraded shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) to “Buy” rating from “Hold” rating and also increased the target price of the company to $52 from $29

• Shares of Key Energy (NYSE:KEG) were upgraded by Weeden to “Buy” rating from “Hold” rating with a target price of $26.00.

KEY ENERGY SVCS (KEG): Free Stock Analysis Report

About Zacks Investment Research 1767 Articles

Zacks Investment Research is one of the most highly regarded firms in the investment industry. In 1978 Zacks originated the concept of utilizing earnings estimates revisions to make profitable investment decisions. Zacks offers multiple investment products and services to help investors achieve superior returns.

Visit: Zacks.com

Be the first to comment

Leave a Reply

Your email address will not be published.


*